These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32529280)

  • 1. Prognostic role of H3K27M mutation, histone H3K27 methylation status, and EZH2 expression in diffuse spinal cord gliomas.
    Ishi Y; Takamiya S; Seki T; Yamazaki K; Hida K; Hatanaka KC; Ishida Y; Oda Y; Tanaka S; Yamaguchi S
    Brain Tumor Pathol; 2020 Jul; 37(3):81-88. PubMed ID: 32529280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
    Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
    Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Midline Glioma in Adults: Clinicopathological, Genetic, and Epigenetic Analysis.
    Enomoto T; Aoki M; Hamasaki M; Abe H; Nonaka M; Inoue T; Nabeshima K
    Neurol Med Chir (Tokyo); 2020 Mar; 60(3):136-146. PubMed ID: 31902873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinicopathological characteristics and prognosis of diffuse midline gliomas with histone H3K27M mutation: an analysis of 30 cases].
    Li HN; Shan CG; Fan CZ; Cheng LN; Wu SG; Liu MT; Jiang GY; Li Z
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):192-198. PubMed ID: 30831644
    [No Abstract]   [Full Text] [Related]  

  • 5. Primary spinal cord gliomas: Pathologic features associated with prognosis.
    Tanaka Y; Natsumeda M; Ohashi M; Saito R; Higa N; Akahane T; Hashidate H; Ito J; Fujii S; Sasaki A; Tanimoto A; Hanaya R; Watanabe K; Oishi M; Kawashima H; Kakita A
    J Neuropathol Exp Neurol; 2024 Dec; 83(12):1010-1019. PubMed ID: 39074166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
    Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
    Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of H3.3 K27M Mutation on Prognosis and Survival of Grade IV Spinal Cord Glioma on the Basis of New 2016 World Health Organization Classification of the Central Nervous System.
    Yi S; Choi S; Shin DA; Kim DS; Choi J; Ha Y; Kim KN; Suh CO; Chang JH; Kim SH; Yoon DH
    Neurosurgery; 2019 May; 84(5):1072-1081. PubMed ID: 29718432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular characteristics of spinal cord gliomas with or without H3 K27M mutation.
    Chai RC; Zhang YW; Liu YQ; Chang YZ; Pang B; Jiang T; Jia WQ; Wang YZ
    Acta Neuropathol Commun; 2020 Mar; 8(1):40. PubMed ID: 32228694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spinal cord high-grade infiltrating gliomas in adults: clinico-pathological and molecular evaluation.
    Alvi MA; Ida CM; Paolini MA; Kerezoudis P; Meyer J; Barr Fritcher EG; Goncalves S; Meyer FB; Bydon M; Raghunathan A
    Mod Pathol; 2019 Sep; 32(9):1236-1243. PubMed ID: 31028365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.
    La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM
    World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas.
    Venneti S; Garimella MT; Sullivan LM; Martinez D; Huse JT; Heguy A; Santi M; Thompson CB; Judkins AR
    Brain Pathol; 2013 Sep; 23(5):558-64. PubMed ID: 23414300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Driver Genetic Mutations in Spinal Cord Gliomas Direct the Degree of Functional Impairment in Tumor-Associated Spinal Cord Injury.
    Nagashima Y; Nishimura Y; Ohka F; Eguchi K; Aoki K; Ito H; Nishii T; Oyama T; Hara M; Kitano Y; Masaki H; Wakabayashi T; Natsume A
    Cells; 2021 Sep; 10(10):. PubMed ID: 34685506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of prognostic markers in diffuse midline gliomas H3K27M-mutant.
    Dufour C; Perbet R; Leblond P; Vasseur R; Stechly L; Pierache A; Reyns N; Touzet G; Le Rhun E; Vinchon M; Maurage CA; Escande F; Renaud F
    Brain Pathol; 2020 Jan; 30(1):179-190. PubMed ID: 31348837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse midline glioma with H3 K27M mutation of the spinal cord: A series of 33 cases.
    Yao J; Wang L; Ge H; Yin H; Piao Y
    Neuropathology; 2021 Jun; 41(3):183-190. PubMed ID: 33599007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis.
    Dhar S; Gadd S; Patel P; Vaynshteyn J; Raju GP; Hashizume R; Brat DJ; Becher OJ
    Acta Neuropathol Commun; 2022 Apr; 10(1):47. PubMed ID: 35395831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebellar high-grade gliomas do not present the same molecular alterations as supratentorial high-grade gliomas and may show histone H3 gene mutations.
    Tauziède-Espariat A; Saffroy R; Pagès M; Pallud J; Legrand L; Besnard A; Lacombe J; Lot G; Borha A; Tazi S; Adle-Biassette H; Polivka M; Lechapt E; Varlet P
    Clin Neuropathol; 2018; 37(5):209-216. PubMed ID: 29809131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma.
    Lee CH; Yu JR; Granat J; Saldaña-Meyer R; Andrade J; LeRoy G; Jin Y; Lund P; Stafford JM; Garcia BA; Ueberheide B; Reinberg D
    Genes Dev; 2019 Oct; 33(19-20):1428-1440. PubMed ID: 31488577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma.
    Ryall S; Krishnatry R; Arnoldo A; Buczkowicz P; Mistry M; Siddaway R; Ling C; Pajovic S; Yu M; Rubin JB; Hukin J; Steinbok P; Bartels U; Bouffet E; Tabori U; Hawkins C
    Acta Neuropathol Commun; 2016 Aug; 4(1):93. PubMed ID: 27577993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.
    Chan KM; Fang D; Gan H; Hashizume R; Yu C; Schroeder M; Gupta N; Mueller S; James CD; Jenkins R; Sarkaria J; Zhang Z
    Genes Dev; 2013 May; 27(9):985-90. PubMed ID: 23603901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse midline glioma-H3K27M mutant. A novel entity with a defining and specific IHC marker.
    Agarwal P; Aiyer HM
    Indian J Pathol Microbiol; 2021; 64(2):351-353. PubMed ID: 33851633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.